MAIN


1994-2020. All Rights Reserved. Online Journal of Veterinary Research. You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJVR publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors.


OJVRTM

Online Journal of Veterinary Research

Volume 23 (4):337-344, 2019.


Effect of oral PLGA/TPGS nanoparticles on stability of vorapaxar and atherosclerosis markers in male albino rats.

 

Adnan M Jasim1, Huda Falah Hasan Alqaraghuli2.

 

College(s) of Veterinary Medicine, 1University of AL-Qassim, 2University of Baghdad, Iraq.

 

ABSTRACT

 

Jasim AM, Hasan Alqaraghuli HF., Effect of oral PLGA/TPGS nanoparticles on stability of vorapaxar and atherosclerosis markers in male albino rats, Onl J Vet Res., 23 (4):337-344, 2019.PLGA-TPGS nanoparticles are used as polymeric matrix to deliver drugs. We describe effective dose (ED50-99) of vorapaxar from a PLGA-TPGS matrix, stability and effect on atherosclerosis platelet and cholesterol markers in male albino rats. Groups of 6 rats with or without atherosclerosis were gavaged ~0.04, 0.08, 0.2, 0.4 and 0.9 mg/kg vorapaxar with or without PLGA-TPGS nanoparticle matrix daily for 30 days to determine ED50-99 from probit analysis. Controls with or without atherosclerosis had no treatment or given distilled water. We found that TPGS-PLGA with nanoparticles < 200nm loaded with Vorapaxar were stable. Given alone the ED50 for vorapaxar was ~0.07, ED90, 0.4 and ED 99 1.6mg/kg but given with TPGS-PLGA was 0.07, 0.1 and 0.17mg/kg, respectively. Compared with healthy controls, we found rises (P < 0.05) in platelets and serum cholesterol in atherosclerotic controls and in those given vorapaxar. In rats given vorapaxar in nanoparticles we found significant reduction in platelets and serum cholesterol compared with those given only vorapaxar.

Key word : Vorapaxar, TPGS/PLGA, nanoparticles, ED50-99.


MAIN

 

 

FULL-TEXT (SUBSCRIBE OR PURCHASE TITLE)